MX385940B - Nuevos antiestrógenos heterocíclicos. - Google Patents

Nuevos antiestrógenos heterocíclicos.

Info

Publication number
MX385940B
MX385940B MX2018005305A MX2018005305A MX385940B MX 385940 B MX385940 B MX 385940B MX 2018005305 A MX2018005305 A MX 2018005305A MX 2018005305 A MX2018005305 A MX 2018005305A MX 385940 B MX385940 B MX 385940B
Authority
MX
Mexico
Prior art keywords
antiestrogens
new heterocyclic
heterocyclic
new
degraders
Prior art date
Application number
MX2018005305A
Other languages
English (en)
Other versions
MX2018005305A (es
Inventor
Amit Pravinbhai Sedani
Bhavesh Mohanbhai Panchal
Dijixa Pinakin Rana
Indraneel Ghosh
Japan Nitinkumar Desai
Jayraj Dilipbhai Aradhye
Kaushikkumar Dhanjibhai Prajapati
Ranjan Kumar Pal
Sandeep Pankajbhai Pathak
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2018005305A publication Critical patent/MX2018005305A/es
Publication of MX385940B publication Critical patent/MX385940B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos heterocíclicos como agentes anticancerígenos, especialmente como antagonistas o degradantes 5 del receptor de estrógeno (ER), así como el proceso para su preparación.
MX2018005305A 2015-10-27 2016-10-26 Nuevos antiestrógenos heterocíclicos. MX385940B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4058MU2015 2015-10-27
PCT/IN2016/050364 WO2017072792A1 (en) 2015-10-27 2016-10-26 Novel heterocyclic antiestrogens

Publications (2)

Publication Number Publication Date
MX2018005305A MX2018005305A (es) 2019-04-29
MX385940B true MX385940B (es) 2025-03-18

Family

ID=58629986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005305A MX385940B (es) 2015-10-27 2016-10-26 Nuevos antiestrógenos heterocíclicos.

Country Status (28)

Country Link
US (2) US10865199B2 (es)
EP (2) EP3368519B1 (es)
JP (2) JP6855475B2 (es)
KR (1) KR20180088375A (es)
CN (1) CN108699021B (es)
AU (1) AU2016347679B2 (es)
BR (1) BR112018008375B1 (es)
CA (1) CA3001958A1 (es)
CY (1) CY1125153T1 (es)
DK (1) DK3368519T3 (es)
EA (1) EA034131B1 (es)
ES (1) ES2916223T3 (es)
HR (1) HRP20220640T1 (es)
HU (1) HUE059386T2 (es)
IL (2) IL283559B (es)
LT (1) LT3368519T (es)
MX (1) MX385940B (es)
PH (1) PH12018500829A1 (es)
PL (1) PL3368519T3 (es)
PT (1) PT3368519T (es)
RS (1) RS63217B1 (es)
SA (1) SA518391423B1 (es)
SG (2) SG11201803119XA (es)
SI (1) SI3368519T1 (es)
SM (1) SMT202200213T1 (es)
UA (1) UA122348C2 (es)
WO (1) WO2017072792A1 (es)
ZA (1) ZA201802615B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803119XA (en) * 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
NZ743651A (en) 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2004091488A2 (en) * 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
WO2006078834A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EA201490897A1 (ru) 2011-12-16 2015-03-31 Олема Фармасьютикалс, Инк. Новые бензопирановые соединения, композиции и их применение
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
SG11201803119XA (en) * 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens

Also Published As

Publication number Publication date
AU2016347679B2 (en) 2020-06-25
ZA201802615B (en) 2022-10-26
EA201890981A1 (ru) 2018-09-28
CY1125153T1 (el) 2024-12-13
AU2016347679A1 (en) 2018-05-10
HUE059386T2 (hu) 2022-11-28
MX2018005305A (es) 2019-04-29
JP6855475B2 (ja) 2021-04-07
SMT202200213T1 (it) 2022-07-21
EA034131B1 (ru) 2020-01-09
BR112018008375A2 (pt) 2018-10-23
WO2017072792A1 (en) 2017-05-04
PH12018500829A1 (en) 2018-10-15
JP2018536647A (ja) 2018-12-13
JP7052111B2 (ja) 2022-04-11
US11465990B2 (en) 2022-10-11
US10865199B2 (en) 2020-12-15
CN108699021B (zh) 2022-10-04
UA122348C2 (uk) 2020-10-26
EP4043438A1 (en) 2022-08-17
BR112018008375B1 (pt) 2023-12-12
CA3001958A1 (en) 2017-05-04
JP2021098749A (ja) 2021-07-01
KR20180088375A (ko) 2018-08-03
HRP20220640T1 (hr) 2022-07-08
PL3368519T3 (pl) 2022-06-06
EP3368519B1 (en) 2022-04-06
IL283559B (en) 2022-07-01
SG10201913001SA (en) 2020-03-30
EP3368519A1 (en) 2018-09-05
US20180354936A1 (en) 2018-12-13
PT3368519T (pt) 2022-05-25
CN108699021A (zh) 2018-10-23
EP3368519A4 (en) 2019-04-10
SG11201803119XA (en) 2018-05-30
IL258949A (en) 2018-06-28
IL283559A (en) 2021-07-29
SA518391423B1 (ar) 2021-03-31
IL258949B (en) 2021-06-30
LT3368519T (lt) 2022-06-10
RS63217B1 (sr) 2022-06-30
DK3368519T3 (da) 2022-05-23
ES2916223T3 (es) 2022-06-29
SI3368519T1 (sl) 2022-07-29
US20210053947A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
CY1125153T1 (el) Νεα ετεροκυκλικα αντiοιστρογονα
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX378998B (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
CR20180563A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
NZ763528A (en) Heterocyclic gpr119 agonist compounds
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2020003224A (es) Moduladores de receptor nuclear.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
ZA202507395B (en) Semaglutide in cardiovascular conditions
CL2017000151A1 (es) Derivados de piridona
AU2016361427A8 (en) Platinum anticancer agents
MX2016015298A (es) Inhibidores de nampt y metodos.
MX2017000519A (es) Derivados de azaspiro(4.5)decano sustituido.
IN2014MU00001A (es)